Some analysts are worried that the artificial intelligence (AI) bubble will burst soon, causing a market crash. Whether or not there's something to these fears, it's a good idea for investors to buy shares of companies that can survive downturns and thrive long after. One stock I'd bet on right now is Eli Lilly (NYSE: LLY). Here's why. The leader in a fast-growing market Eli Lilly has historically been one of the largest players in the diabetes medicine market, and it remains so today. However, over the ...

Core Insights - Novo Nordisk is focusing on regaining market share in the GLP-1 space, where it has faced competition from Eli Lilly [1][8] - The company's future growth will depend on the success of its next-generation therapies, particularly CagriSema, as current products are expected to see declining sales [2][6] Product Development - CagriSema is a dual agonist that mimics GLP-1 and amylin, showing promising results in clinical trials [4] - In a phase 3 weight-loss trial, CagriSema achieved a mean weight reduction of 22.7% after 68 weeks, outperforming Wegovy, which had a reduction of 16.1% [4] - Another late-stage study showed CagriSema led to a 1.91% reduction in blood sugar and a 14.2% weight loss in type 2 diabetes patients, surpassing Ozempic's performance [5] Regulatory and Manufacturing Challenges - Novo Nordisk has submitted regulatory applications for CagriSema as a weight loss treatment and plans to seek approval for diabetes treatment after completing additional studies [6] - CagriSema's manufacturing will be more complex and costly compared to semaglutide, which has faced supply constraints [7] Competitive Landscape - Eli Lilly's retatrutide has shown a mean weight loss of up to 28.7%, indicating that Novo Nordisk still faces significant competition [7] - Despite challenges, CagriSema's advantages over Wegovy and Ozempic may enhance Novo Nordisk's market position as the company expands its manufacturing capacity [8] Revenue Potential - Wegovy has received label expansions for treating metabolic dysfunction-associated steatohepatitis (MASH), which could positively impact sales [9] - New approvals and label expansions may help Novo Nordisk's revenue trajectory improve [9]

Core Viewpoint - Eli Lilly's strong performance is largely attributed to its successful clinical and commercial progress with tirzepatide, a drug approved for diabetes and weight loss, which is driving rapid sales growth and excellent financial results [1] Group 1: Clinical and Commercial Progress - Eli Lilly's weight loss portfolio, particularly tirzepatide, is expected to remain the biggest growth driver in the foreseeable future [1] - The company has achieved positive outcomes for nearly all R&D key events in 2025, a rare achievement in the pharmaceutical industry [3] - Eli Lilly's retatrutide and orforglipron have shown promising results in phase 3 studies, contributing to the company's success in weight management and diabetes [3] Group 2: Broader Therapeutic Advances - Eli Lilly has made significant clinical progress in other therapeutic areas, including cancer and Alzheimer's disease, with Jaypirca excelling in a phase 3 study and Kisunla showing promise in slowing cognitive decline [4] - The company's innovative approach in R&D is performing better than many peers in the industry, highlighting its competitive edge [4] Group 3: Investment in Technology - Eli Lilly is investing in artificial intelligence (AI) to enhance its clinical trial success rate and accelerate drug development, including plans to build the industry's largest AI supercomputer [5] - The U.S. Food and Drug Administration's recognition of AI's value in drug discovery supports Eli Lilly's strategic direction in leveraging technology for future advancements [5]

Core Insights - Eli Lilly has become the largest healthcare company and the first to reach a market capitalization of $1 trillion, outperforming broader equities over the past five years [1] Financial Performance - Eli Lilly reported exceptional financial results, with fourth-quarter sales of $19.3 billion, reflecting a 43% year-over-year increase, and adjusted earnings per share of $7.54, up 42% compared to the previous year [3] - The company anticipates revenue between $80 billion and $83 billion for the current year, indicating a top-line growth of 25% at the midpoint, which exceeds analysts' expectations despite price reductions on key medicines [4] Market Position - Eli Lilly is gaining significant ground in the diabetes and weight management market, with its tirzepatide drug generating over $30 billion in sales in 2025, making it the world's best-selling compound [5] - The company's market share for incretin analogs has increased to 60.5% by the end of 2025, while competitor Novo Nordisk's share has decreased to 39.1%, indicating Lilly's dominance in this sector [6] Pipeline Development - Eli Lilly has several promising pipeline candidates, including an oral GLP-1 medicine, orforglipron, expected to gain approval by the second quarter of 2026, and retatrutide, which has shown excellent phase 3 results targeting weight loss [7]

Core Insights - Equity markets are showing potential for more stocks to join the $1 trillion club, supported by strong fundamentals and market optimism [1][2] Group 1: Eli Lilly (NYSE: LLY) - Eli Lilly is the closest candidate to reach the $1 trillion market capitalization, currently at approximately $948.6 billion, needing a gain of about 5.4% [3] - The growth is driven by increasing demand for its GLP-1 portfolio, particularly Mounjaro for diabetes and Zepbound for obesity, with revenue growth exceeding 40% year over year [3][4] - Management has provided a 2026 revenue guidance of $80 billion to $83 billion, significantly above market expectations, supported by expanded supply and improved manufacturing capacity [4][6] Group 2: JPMorgan Chase (NYSE: JPM) - JPMorgan Chase, with a market capitalization of about $877.7 billion, requires a gain of roughly 14% to reach the $1 trillion milestone, making it a credible contender in the financial sector [7] - The bank's latest earnings reflect strength across investment banking, trading, and consumer businesses, despite increased technology spending and balance sheet adjustments [9] - Management anticipates easing expense pressures and stable revenues, with expectations for U.S. interest-rate cuts later in 2026 alleviating concerns over net interest income volatility [9][10]

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Extremely Profitable Stocks to Invest in Now. Analysts Project Eli Lilly (LLY) to Deliver 21%+ Revenue Growth and 40%+ Adjusted Earnings Growth in 2026 Pixabay/Public Domain On February 2, 2026, Reuters reported that long-standing expectations that the global obesity drug market would reach $150 billion over the next decade are being reconsidered amid declining U.S. prices for GLP-1 therapies and intensifying competition. The new projections indicat ...

证券研究报告 行业周报 礼来替尔泊肽全线爆发，2025年合计贡献365亿美元 生物医药行业强于大市（维持） 平安证券研究所生物医药团队 分析师： 叶寅投资咨询资格编号:S1060514100001邮箱：YEYIN757@PINGAN.COM.CN 倪亦道投资咨询资格编号:S1060518070001邮箱：NIYIDAO242@PINGAN.COM.CN 韩盟盟投资咨询资格编号:S1060519060002邮箱：HANMENGMENG005@PINGAN.COM.CN 裴晓鹏投资咨询资格编号:S1060523090002邮箱：PEIXIAOPENG719@PINGAN.COM.CN 何敏秀投资咨询资格编号:S1060524030001邮箱：HEMINXIU894@PINGAN.COM.CN 王钰畅投资咨询资格编号:S1060524090001邮箱：WANGYUCHANG804@PINGAN.COM.CN 曹艳凯投资咨询资格编号:S1060524120001邮箱：CAOYANKAI947@PINGAN.COM.CN 张梦鸽投资咨询资格编号:S1060525070003邮箱：ZHANGMENGGE752@PINGA ...

Eli Lilly and Company (NYSE:LLY) is one of the best long term low volatility stocks to invest in. Eli Lilly and Company (NYSE:LLY) announced on January 30 significant plans to invest over $3.5 billion in a new manufacturing facility in the Lehigh Valley, Pennsylvania, which would function as the company’s newest injectable medicine and device manufacturing facility, producing next-generation weight-loss therapies. These include retatrutide, a first-in-class investigational GIP, GLP-1, and glucagon triple h ...

礼来公司表示，将斥资超过35亿美元在美国宾州利哈伊谷建造一座制造厂，为公司于美国进行的一系列 新投资项目中的第四间厂，该厂将有助于生产其下一代肥胖药物。公司指，其中包括实验性药物 retatrutide，该药物在后期试验中显示出迄今为止所有治疗方法中最高的减肥效果。公司预计宾州工厂 将于今年开工建设，并于2031年投入营运。 ...

Core Viewpoint - Eli Lilly and Co. is expanding its domestic production capabilities by investing $3.5 billion in a new manufacturing facility in Pennsylvania, driven by the increasing sales of its obesity and diabetes treatments [1]. Group 1: Expansion Plans - The new plant will be located in Fogelsville, Pennsylvania, and is expected to produce injectable drugs and devices, including the weight-loss drug retatrutide, which is currently under study [3]. - This facility is part of a broader domestic expansion strategy that includes new plants in Texas, Virginia, and Alabama, along with an ongoing construction project in Indiana [2]. Group 2: Financial Performance - Eli Lilly reported a record third-quarter profit of $5.58 billion, with total revenue reaching $17.6 billion, reflecting an increase of over 50% compared to the same quarter last year [4]. - Sales from Zepbound and Mounjaro contributed significantly, accounting for $10 billion in sales during the third quarter [4].